Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

How much is brand name vyvanse?

See the DrugPatentWatch profile for vyvanse

In the United States, a 30‑day supply of brand‑name Vyvanse (30 mg) typically costs $300–$400 if you’re paying out‑of‑pocket. Prices can fluctuate based on:

| Factor | Effect on Cost |
|--------|----------------|
| Dosage strength | Higher strengths (e.g., 60 mg or 70 mg) can add $50–$80 per month. |
| Pharmacy | Some chains or online retailers offer lower list prices; GoodRx or other comparison tools can show $10–$20 savings. |
| Insurance coverage | With a prescription plan, you may pay only a copay or coinsurance (often $10–$25). |
| Manufacturer discount cards | The Vyvanse “Savings Card” can reduce the net price by up to 30 %. |
| Location | Prices can be a bit higher in rural or high‑cost areas. |

Typical range (without insurance):
- 30 mg: $300–$350 per month
- 60 mg: $350–$450 per month
- 70 mg: $400–$500 per month

These figures are averages from recent pharmacy listings (e.g., GoodRx, Walmart, CVS) and may vary slightly over time. If you’re looking for the exact price at a specific pharmacy, it’s best to check online or call the pharmacy directly. If you have insurance, contacting your provider or the pharmacy’s benefits department can give you a more accurate out‑of‑pocket estimate.



Other Questions About Vyvanse :

vyvanse generic manufacturers Getting off vyvanse for a night out? Vyvanse generic availability? Vyvanse scientific name? Vyvanse generic manufacturer? Vyvanse online sales? Generic vyvanse canada?

AI-Drug Label Prescribing Information Alignment Report

100
100%
Grade A

Excellent

Mostly Aligned

Patient Risk: Low

Summary

The provided claim about Vyvanse’s boxed warning content (high abuse/misuse potential leading to substance use disorder/addiction and increased overdose/death risk, including with higher doses and unapproved methods such as snorting or injection) is directly supported by the supplied FDA label excerpts (Boxed Warning and Warnings/Precautions and Drug Abuse/Dependence).


Category Scores

Dosage
90
Good
Warnings
100
Excellent

Accurate Statements

VYVANSE has a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction.
Supported by BOX (Abuse, Misuse, and Addiction) and also reiterated in Warnings and Precautions (5.1) and Drug Abuse and Dependence (9.2).
Misuse and abuse of CNS stimulants, including VYVANSE, can result in overdose and death.
Supported by BOX and Warnings and Precautions (5.1), and consistent with Drug Abuse and Dependence (9.2) excerpt provided.
The risk is increased with higher doses or unapproved methods of administration, such as snorting or injection.
Supported by BOX (and consistent with 5.1 and 9.2 excerpts provided), explicitly naming higher doses and unapproved methods including snorting or injection.

Unsupported Statements


Contradictions


Important Omissions

No prescriber-facing mitigation elements from the boxed warning (e.g., assess each patient's risk before prescribing, educate patients/families, proper storage/disposal, and frequently monitor for signs/symptoms) were included alongside the abuse/misuse risk statement.
Importance: Moderate

Safety Assessment

Potential Patient Risk: Low
The evaluated claim is consistent with the label’s abuse/misuse boxed warning and does not introduce dosing, contraindication, or interaction instructions beyond what the label excerpt supports.

Regulatory Assessment

On Label Yes
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Low

Recommendation

Mostly Aligned

Primary Issue
Omitted label-recommended prescriber/patient management actions that accompany the boxed warning (risk assessment, education, storage/disposal instructions, and frequent monitoring).

Suggested Improvement
Include the boxed warning’s accompanying actions (assess risk before prescribing, educate patients/families about abuse/misuse risk and proper storage/disposal, reassess risk throughout treatment, and frequently monitor for signs/symptoms of abuse/misuse/addiction) when summarizing the boxed warning.